Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mitotic index

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Mitotic index. Displaying page 1 of 1.
    EudraCT Number: 2018-002013-35 Sponsor Protocol Number: FORESIGHT Start Date*: 2018-10-19
    Sponsor Name:VU University Medical Center
    Full Title: FES (16α-[18F]-fluoro-17β-estradiol)-PET: Towards a new standard to stage clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET an...
    Medical condition: Breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000762-18 Sponsor Protocol Number: CRN00808-11 Start Date*: 2023-01-24
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.
    Medical condition: Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004992-62 Sponsor Protocol Number: A-US-52030-328 Start Date*: 2016-11-14
    Sponsor Name:Ipsen Biopharmaceuticals, Inc
    Full Title: A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH...
    Medical condition: Lung Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) DK (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022713-26 Sponsor Protocol Number: CAMN107DDE12 Start Date*: 2011-03-30
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at ...
    Medical condition: localized gastrointestinal stromal tumors (GIST)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000507-12 Sponsor Protocol Number: RYZ101-301 Start Date*: 2023-06-12
    Sponsor Name:RayzeBio, Inc.
    Full Title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing...
    Medical condition: gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000415-23 Sponsor Protocol Number: PM14-A-002-20 Start Date*: 2021-05-25
    Sponsor Name:Pharma Mar, S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004163-12 Sponsor Protocol Number: 2020-012-GLOB1 Start Date*: 2021-11-04
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004648-44 Sponsor Protocol Number: MedOPP253 Start Date*: 2020-07-06
    Sponsor Name:Medica Scientia Innovation Research S.L (MEDSIR)
    Full Title: A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pre...
    Medical condition: UNRESECTABLE LOCALLY ADVANCED OR METASTATIC RIPLE-NEGATIVE BREAST CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Nov 21 18:18:45 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA